RTP Mobile Logo

Friday, May 1, 2020, San Antonio, Texas, 6:00 PM – 8:00 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA CNE (NCPD) Symposia Series Associated with the ONS 45th Annual Congress

Breast Cancer

Update regarding COVID-19

The ONS Board of Directors has made the difficult decision to cancel the 45th Annual ONS Congress scheduled to take place in San Antonio, April 29-May 3, 2020. ONS is exploring alternatives for delivering the educational sessions. For up-to-date information on this program, please sign up for our email alerts.

Last updated 4/8/2020

Event Details

Grand Hyatt San Antonio
600 East Market Street
San Antonio, TX 78205

Hotel Phone: (210) 224-1234

Meeting Room
Texas Ballroom ABC (Fourth Floor)
5:30 PM – 6:00 PM
Registration and Dinner Buffet

6:00 PM – 8:00 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Jamie Carroll, APRN, MSN, CNP
Mayo Clinic
Rochester, Minnesota

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in
Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas

Madelaine C Kuiper, NP
Nurse Practitioner
University of California, Los Angeles
Santa Monica, California

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast
Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Novartis, Puma Biotechnology Inc and Seattle Genetics during the Oncology Nursing Society’s (ONS) 45th Annual Congress, April 29 to May 3, 2020 in San Antonio, Texas. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


Topics for Discussion

  • Module 1: Neoadjuvant, Adjuvant and Extended Adjuvant Therapy for Patients with Localized HER2-Positive Breast Cancer (BC)
  • Module 2: Protocol and Off-Protocol Decision-Making for Patients with HER2-Positive Metastatic BC (mBC)
  • Module 3: Evolving Treatment Paradigms in the Management of ER-Positive mBC
  • Module 4: Role of Immune Checkpoint Inhibition in the Treatment of mBC
A detailed agenda will be made available by late March.

CE Information

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer (BC).

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with early and advanced breast cancer.
  • Consider available and emerging research evidence to individualize the selection of neoadjuvant, adju­vant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of HER2-positive metastatic breast cancer (mBC), incorporating existing and investigational targeted treatments.
  • Appreciate the biologic rationale for and available data with novel immunotherapeutic approaches to facilitate their introduction into clinical practice for appropriate patients with mBC.
  • Appraise published efficacy and safety data with the use of PARP inhibitors for patients with mBC har­boring a BRCA1/2 mutation, and consider the diagnostic and therapeutic implications of these find­ings for nonresearch care.
  • Recognize the FDA-endorsed indications for the commercially available CDK4/6 inhibitors, and dis­cern how these agents can be optimally employed in the nonresearch care of patients with ER-positive mBC.
  • Develop an understanding of the frequency of PIK3CA mutations in patients with ER-positive mBC previously treated with endocrine therapy, and appreciate published research data documenting the effi­cacy and safety of novel agents targeting this abnormality.
  • Develop a plan to manage the side effects associated with available and recently approved systemic ther­apies to support quality of life and continuation of treatment.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive bio­psychosocial care of patients with breast cancer to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by RTP.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Novartis, Puma Biotechnology Inc and Seattle Genetics.


Grand Hyatt San Antonio
600 East Market Street
San Antonio, TX 78205

Hotel Phone: (210) 224-1234

Meeting Room
Texas Ballroom ABC (Fourth Floor)

The Grand Hyatt San Antonio is conveniently located adjacent and connected to the Henry B Gonzalez Convention Center, where the ONS 45th Annual Congress is taking place.